Owing to the strong association with NF1 loss, most preclinical MPNST models have been developed in NF1-deficient systems, either alone or combined with conditional deletion of additional tumor suppressors such as Tp53 (also known as Trp53) or Cdkn2a (Mohamad et al., 2021). The gene discussed is TP53; the disease is neoplasm.